Highlights

  • Saluda Medical (ASX:SLD) develops closed-loop spinal cord stimulation technology for chronic pain.
  • FDA approval and first US use of the CAP24 Surgical Paddle Lead broadened the Evoke platform during 2026.
  • EVA Sensing Technology has also expanded the company’s regulatory and commercial reach across key markets.
  • The next stage of the story depends on clinician adoption, Revenue growth, reimbursement and commercial execution.

Saluda Medical (ASX:SLD), which trades on the ASX through CHESS Depository Interests, is one of the more differentiated medical-device names available to Australian investors. The company develops closed-loop spinal cord stimulation systems for chronic pain, using technology designed to sense the spinal cord’s physiological response and automatically adjust stimulation in real time.

That approach is built around Evoked Compound Action Potentials, or ECAPs, and is commercialised through Saluda’s Evoke platform. With several regulatory and product milestones already achieved during 2026, attention is increasingly shifting from technology validation towards commercial adoption.

Recent catalysts have been regulatory and commercial

Saluda Medical (ASX:SLD) has delivered a sequence of regulatory and market-access milestones.

On 30 June 2026, the company announced US FDA approval for its CAP24 Surgical Paddle Lead. On 16 July 2026, it reported the first US surgical cases using the newly approved lead.

The approval broadens the range of procedures and patients that can be addressed through the Evoke platform. Moving quickly from regulatory clearance to first clinical use is also an important operational step because it begins the process of converting product approval into real-world adoption.

Earlier in 2026, Saluda also announced that its EVA Sensing Technology had received regulatory approval in Europe with recognition in Australia, extending the reach of its closed-loop technology across additional markets.

Together, these developments show a company widening both its product offering and its commercial footprint.

The technology and evidence base

Saluda Medical’s (ASX:SLD) core proposition is that its Evoke System can continuously measure the spinal cord’s response to stimulation and adjust therapy accordingly.

Traditional spinal cord stimulation systems generally deliver programmed pulses without continuously measuring the physiological response of the spinal cord. Saluda’s closed-loop approach is designed to maintain therapy within a more consistent therapeutic range.

The company has built its technology around an extensive ECAP data set and a body of clinical research, including the EVOKE randomised study and longer-term follow-up data.

For investors, the evidence base matters because adoption in neuromodulation depends not only on product features, but also on whether clinicians, hospitals and payers see durable clinical benefits.

Published outcomes can therefore play an important role in supporting reimbursement discussions, physician confidence and switching from established competing systems.

Balance sheet and leadership

Saluda Medical strengthened its funding position in December 2025 through a US$150 million Capital raise following its ASX IPO.

That capital provides additional resources to support commercial expansion, salesforce development, product launches and broader market penetration as the company scales its operations.

Leadership has also evolved alongside the commercialisation effort. Barry Regan was appointed Chief Executive Officer in mid-2025, with the broader management structure including commercial and finance Leadership aimed at supporting the next stage of growth.

For a medical-device company at this point in its development, capital deployment will be important. Spending needs to support commercial growth while remaining disciplined enough to extend the runway towards a more self-sustaining operating model.

Catalysts to watch and key risks

The next catalysts are increasingly commercial rather than scientific.

One of the clearest indicators will be the pace of CAP24 adoption in the United States. Early procedures establish initial clinical use, but broader uptake across surgical centres will provide a better indication of commercial traction.

US revenue growth from EVA Sensing Technology and the Evoke SmartLoop platform will also be important, particularly because the US neuromodulation market is highly competitive and commercially significant.

Expansion across Europe and Australia represents another opportunity, although market penetration will depend on reimbursement, physician training, hospital adoption and local commercial execution.

Quarterly updates and financial results should provide evidence of whether the company’s growing regulatory footprint is translating into higher sales and improved operating leverage.

The risks remain meaningful. Saluda Medical (ASX:SLD) competes with much larger and better-capitalised medical-device companies that already have established surgeon relationships and extensive distribution networks.

Changing physician behaviour can also take time, even when a new technology offers differentiated features. Clinicians may be reluctant to change established treatment pathways without clear evidence of improved outcomes and reimbursement support.

The company may also remain loss-making while it scales commercial operations, making cost control and capital management important considerations.

Its US-centred operating base combined with ASX-listed CDIs also introduces currency and structure considerations for Australian investors.

On balance, Saluda Medical (ASX:SLD) has moved through an important sequence of regulatory and product milestones, supported by a differentiated closed-loop spinal cord stimulation platform and an established clinical evidence base. The next phase will depend on whether those advantages translate into broader physician adoption, sustained revenue growth and improving commercial economics.